All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

Jakarta EE, a working group hosted by the Eclipse Foundation, today announced the general availability of the Jakarta EE 11 Platform, the latest version of its enterprise Java platform.

GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links. Relooted Is Like A Reverse Indiana Jones Take from the museums ...

A disaster recovery program in California includes help for forward and reverse mortgage borrowers, drawing praise from reverse professionals.

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

Federal workers who help run the health program for Sept. 11 first responders and survivors have been rehired after a bipartisan outcry forced the Trump administration to reverse deep cuts that ...